Drugs / Iparomlimab and Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06878222 | Mar 2025 → Mar 2028 expected | cervical cancer | Obstetrics & Gynecology Hospital of Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and Tuvonralimab | “Iparomlimab and Tuvonralimab is a novel therapeutic biological product targeting both PD-1 and CTLA-4.” NCT06878222 ↗ |
| Modality | Monoclonal antibody | “It is composed of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4) expressed in a fixed ratio and produced as a single product from a single cell line.” NCT06878222 ↗ |